Governance Tempus AI, Inc.

TEM

US88023B1035

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 18/04/2026 am IST			After hours 05:30:00 am
55.87 ^USD	+2.66%		55.54	-0.58%

15/04	Tempus AI, Inc. And Predicta Biosciences Announce Collaboration To Expand Life Sciences Access To Ultrasensitive Whole-Genome Sequencing Assay For Hematologic Malignancies And MRD Monitoring	CI
15/04	Tempus AI, Predicta Biosciences Partner to Broaden Access to Ultrasensitive WGS Assay	MT

Executive Committee: Tempus AI, Inc.

Manager

Positions heldSince

Eric Lefkofsky

56 year

Chief Executive Officer	01/08/2015
Founder	01/08/2015

Patrick Rogers

40 year

Director of Finance/CFO

01/08/2017

Ryan Bartolucci

44 year

Comptroller/Controller/Auditor

01/05/2021

Elizabeth Krutoholow

Investor Relations Contact

01/05/2023

A. Sasser

49 year

Chief Tech/Sci/R&D Officer

25/10/2022

Stacey Y. Kraft

Human Resources Officer

01/05/2022

Erik Phelps

55 year

Chief Administrative Officer	01/06/2020
General Counsel	01/06/2020

Andrew Polovin

52 year

General Counsel	01/06/2020
Corporate Secretary	01/04/2024

Ryan Fukushima

40 year

Chief Operating Officer

01/09/2015

Composition of the Board of Directors: Tempus AI, Inc.

Director

CommitteesSince

Eric Lefkofsky

56 year

Executive Committee

Wayne Frederick

54 year

Compensation Committee Chair	20/02/2020
Organization Committee Chair	20/02/2020
Compensation Committee	20/10/2020
HR Committee	20/10/2020
Governance Committee	22/06/2022
Nominating Committee	22/06/2022
Audit Committee
Governance Committee Chair

Theodore Leonsis

70 year

Compensation Committee	19/07/2010
Governance Committee	19/07/2010
Nominating Committee	19/07/2010
Audit Committee
Executive Committee	01/01/2019
Governance Committee Chair	01/01/2019
Nominating Committee Chair	01/01/2019

Peter Barris

74 year

Finance Committee
Audit Committee	01/09/2017
Governance Committee	01/02/2011
Nominating Committee	01/02/2011
Executive Committee	01/09/2017
Compensation Committee Chair	01/09/2017

Nadja West

64 year

Audit Committee	05/09/2019
Executive Committee	05/09/2019
Compensation Committee	01/04/2021
Governance Committee	07/10/2019
Nominating Committee	07/10/2019

David Epstein

64 year

Compensation Committee	20/02/2024
Governance Committee	20/02/2024
Nominating Committee	20/02/2024

Scott Gottlieb

54 year

Governance Committee	28/03/2025
Nominating Committee	28/03/2025
Executive Committee

Jennifer Doudna

62 year

Governance Committee	01/04/2021
Nominating Committee	01/04/2021

Eric Belcher

57 year

Audit Committee Chair

01/01/2019

Latest Appointments: Tempus AI, Inc.

19/11	UnitedHealth Group Appoints Scott Gottlieb to Its Board of Directors as an Independent Director, Effective November 18, 2025	CI
18/25/18	Tempus AI, Inc. Unveils Advisory Board Featuring Leading Physicians from Across the U.S	CI

More news

Former Officers and Directors: Tempus AI, Inc.

Insider

Positions held

SinceUntil

Marc Yoskowitz

Corporate Officer/Principal

01/02/2019

01/01/2024

Joel Dudley

Consultant / Advisor	01/08/2022	01/08/2023
Chief Tech/Sci/R&D Officer	01/08/2020	01/08/2022
Corporate Officer/Principal	01/10/2019	01/09/2020

Kimberly Blackwell

Chief Tech/Sci/R&D Officer

01/03/2020

16/05/2022

Kevin P. White

Chief Tech/Sci/R&D Officer	-	01/09/2020
President	-	-

Trisha Degg

Corporate Officer/Principal

01/11/2019

01/06/2020

Robert Ghenchev

Director/Board Member

01/05/2019

Brad Keywell

Corporate Officer/Principal

01/08/2015

Age distribution of managers

Parity Men Women

Male	16
Female	3

Of which Executive Committee

Male	7
Female	2

Of which Directors

Male	9
Female	0

Revisions

Recommandations analystes

Évolution recommandations analystes 1 an

Évolution recommandations analystes 4 mois

Objectif analystes

Évolution objectif analystes 1 an

Évolution objectif analystes 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Controverses sur les droits de l'Homme

Controverses Subventions fiscales

Conforme à la finance Islamique

Tempus AI, Inc. is a technology company. The Company provides next generation diagnostics across multiple disease areas, with technology capabilities, harnessing the data and analytics to help personalize medicine. The Companyâ€™s product lines include genomics, data, and artificial intelligence applications (AI). Its genomics product line leverages its laboratories to provide next generation sequencing, diagnostics, polymerase chain reaction (PCR), profiling, molecular genotyping, and other anatomic and molecular pathology testing. The Company's AI applications are focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools. Its primary product of AI applications is Next, an AI platform that leverages machine learning to apply an intelligent layer onto routinely generated data to proactively identify and minimize care gaps for oncology and cardiology patients.

Employees

3,800

Sector

Biotechnology & Medical Research

More about the company